V181 High-Potency Level + V181 Mid-Potency Level + V181 Low-Potency Level + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dengue Disease
Conditions
Dengue Disease, Dengue Virus
Trial Timeline
Sep 7, 2022 → May 7, 2024
NCT ID
NCT05507450About V181 High-Potency Level + V181 Mid-Potency Level + V181 Low-Potency Level + Placebo
V181 High-Potency Level + V181 Mid-Potency Level + V181 Low-Potency Level + Placebo is a phase 2 stage product being developed by Merck for Dengue Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05507450. Target conditions include Dengue Disease, Dengue Virus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05507450 | Phase 2 | Completed |
Competing Products
20 competing products in Dengue Disease